Elizabeth M Burton

11PUBLICATIONS
202CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 18, 2026
Pathological assessment of neoadjuvant-treated melanoma specimens: a historical overview, lessons learned along the way and the road ahead.

|Oct 01, 2026
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

|Sep 02, 2026
Functionally active lymphoid aggregates correlate with improved prognosis in brain metastases.

|Jul 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.

Elizabeth M Burton, Denái R Milton, Michael T Tetzlaff

|Mar 25, 2025
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma.

Li Zhou, Milton Jose Barros E Silva, Edward Hsiao

|Apr 08, 2024
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.

Isabella C Glitza, Yongwoo David Seo, Christine N Spencer

Pageof 2

Frequent Collaborators

8 joint publications

Hussein A Tawbi

4 joint publications

Michael A Davies

4 joint publications

Alexander Lazar

3 joint publications

Christine N Spencer